Drug Trial Radar · NCT04770753
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
194
Actual
Start
Dec 20, 2021
Primary completion
Nov 13, 2023
Study completion Dec 2028
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study was to compare the effect of mitapivat versus placebo on hemolytic anemia in participants with alpha- or beta-non-transfusion dependent thalassemia (NTDT).
Conditions
- Non-Transfusion-dependent Alpha-Thalassemia
- Non-Transfusion-dependent Beta-Thalassemia
Interventions
Placebo Matching MitapivatDrug
Tablets
MitapivatDrug
Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With BaselineTime frame: Double-Blind Period: Baseline up to Week 12 through Week 24
Locations
68 sites in 18 countries. Site status is shown where the registry gives one.
San Diego Hospital, UC San Diego Health
La Jolla, California
Stanford Medicine
Palo Alto, California
Massachusetts General Hospital
Boston, Massachusetts
Weill Cornell Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Penn Medicine - University of Pennsylvania Health System
Philadelphia, Pennsylvania
Universidade de Caxias do Sul
Caxias do Sul, Brazil
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
Ribeirão Preto, Brazil
HEMORIO Instituto Nacional de Hematologia
Rio de Janeiro, Brazil
Praxis Pesquisa Medica
Santo André, Brazil
GSH Banco de Sangue de São Paulo
São Paulo, Brazil
Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidad de São Paulo
São Paulo, Brazil
MHAT "Dr. Nikola Vasiliev" AD
Kyustendil, Bulgaria
SHATHD Sofia
Sofia, Bulgaria
Toronto General Hospital, University Health Network
Toronto, Canada
Rigshospitalet
Copenhagen, Denmark
CHU Hôpital Henri Mondor
Créteil, France
Hopital Edouard Herriot, CHU de Lyon
Lyon, France
Laiko General Hospital
Athens, Greece
Children's Hospital Agia Sophia, National and Kapodistrian University of Athens Medical School
Athens, Greece
University General Hospital of Patras
Rio, Greece
Ippokrateio General Hospital
Thessaloniki, Greece
Ospedale "A. Perrino" - Brindisi
Brindisi, Italy
Ospedale Pediatrico Microcitemico
Cagliari, Italy
Ospedale Sant'Anna
Ferrara, Italy
Ente Ospedaliero Ospedali Galliera
Genova, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
A.O.U Di Modena
Modena, Italy
A.O.R.N. "A. Cardarelli"
Naples, Italy
AOU L. Vanvitelli Universita degli Studi della Campania Luigi Vanvitelli
Naples, Italy
A.O.U. San Luigi Gonzaga
Orbassano, Italy
Chronic Care Center
Beirut, Lebanon
Hospital Sultanah Bahiyah
Alor Star, Malaysia
Hospital Ampang
Ampang, Malaysia
Hospital Sultanah Aminah Johor Bahru
Johor Bahru, Malaysia
Hospital Queen Elizabeth, Kota Kinabalu
Kota Kinabalu, Malaysia
Hospital Tunku Azizah
Kuala Lumpur, Malaysia
Hospital Tengku Ampuan Afzan
Kuantan, Malaysia
Hospital Umum Sarawak
Kuching, Malaysia
Hospital Pulau Pinang
Pulau Pinang, Malaysia
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.